New shot for rare Heart/Nerve disease passes first safety check
NCT ID NCT05661916
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This early-stage study tested a single injection of an experimental drug (ALN-TTRSC04) in 96 healthy adults to see if it is safe and how the body processes it. The drug aims to lower a harmful protein that causes transthyretin-mediated amyloidosis, a rare disease affecting the heart and nerves. No treatment was given to patients yet; this was a first step to find the right dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
London, SE1 1YR, United Kingdom
Conditions
Explore the condition pages connected to this study.